Exenatide Reduces Urinary Transforming Growth Factor-ß1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

(2011) R. Kodera et al.   DIABETOLOGIA

Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level

(2011) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

Prevalence of Diabetes among Men and Women in China

(2010) Wenying Yang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

(2009) Kunio Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor

(2009) Christina Rye Underwood et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides

(2009) Rania Abu-Hamdah et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia

(2009) Mamdouh H. Kedees et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY